Archived explainer. For the current picture see today's NVAX page.
NOVAVAX INC (NVAX) is down -9.87% in the latest session. Our newswire has captured 7 stories on NVAX across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 52/100).
Novavax Inc (NVAX) shares fell 9.87% to $11.32 on Tuesday, reversing a recent upward trend that had seen the stock rise 6.5% over the previous eight sessions. The decline followed a shift in sentiment as the World Health Organization downplayed the risk of a wider plague outbreak after a suspected pneumonic plague death in Russia. The reassessment reduced speculative demand for vaccine stocks, particularly affecting Novavax, which had surged earlier in the week on similar fears.
The stock had previously climbed 22% as Sanofi began distributing Novavax’s Nuvaxovid vaccine for the fall season. However, the recent plunge came after the WHO and Russian health officials indicated the risk of a broader outbreak remains low. This shift in public health messaging caused investors to unwind positions in speculative biotech plays. Earlier in the day, Novavax shares had joined a broader rally in vaccine-related stocks after news of a lab worker’s death in Siberia sparked temporary concern. However, the absence of confirmed cases or government procurement announcements left the move vulnerable to reversal.
The stock has traded between $6.20 and $13.38 over the past 52 weeks and remains unprofitable, with a trailing twelve-month net margin of -59.9%. The recent session saw unusual options activity, with $10.2 million in call premiums and $1.1 million in put premiums. The largest single print was $1.5 million. On the same day, the stock printed one fresh 52-week high and six 52-week lows. Trading volume was elevated, though specific figures were not provided.
Investors should monitor the company’s upcoming earnings report, if any, and broader market reactions to evolving public health developments. Coverage of the stock has increased in the past 36 hours, with seven stories from five different sources.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Shares of vaccine developer Novavax ($NVAX) plunged on Tuesday after the World Health Organization said that the risk of a wider plague outbreak remains low. The dr...
A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low. That reversal in sentiment lands hardest on Novavax (NASDAQ:NVAX), since the company’s rally priced a government-purchase scenario that its product line doesn’t address. Novavax stock trades at $12.32, down 2% in morning […]
Novavax (NVAX) stock and Moderna (MRNA) stock trade flat after WHO updates on a suspected pneumonic plague death in Russia. Read more here.
No plague case has been confirmed, and no government orders have been announced, but outbreak-linked stocks jumped anyway.
Vaxcyte said earlier on Monday that its experimental pneumonia vaccine, VAX-31, met the main goals of a late-stage study in adults 50 and older.
Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewarding shares of licensor Novavax (NASDAQ:NVAX) far more heavily than the rest of biotech. Novavax stock has rose 17% during afternoon trading, reaching $12.28, a move that stands well apart from its closest vaccine rivals and the broader sector. Checking […]
Why is Novavax stock surging today?
More on NVAX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier NVAX move explainers: 2026-10-07 · 2026-10-06 · 2026-10-05 · 2026-09-10 · 2026-09-02 · 2026-09-01 · 2026-08-28